These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 15948676

  • 1. Glucagon as a target for the treatment of Type 2 diabetes.
    Sloop KW, Michael MD, Moyers JS.
    Expert Opin Ther Targets; 2005 Jun; 9(3):593-600. PubMed ID: 15948676
    [Abstract] [Full Text] [Related]

  • 2. Glucagon antagonism as a potential therapeutic target in type 2 diabetes.
    Bagger JI, Knop FK, Holst JJ, Vilsbøll T.
    Diabetes Obes Metab; 2011 Nov; 13(11):965-71. PubMed ID: 21615669
    [Abstract] [Full Text] [Related]

  • 3. Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes.
    Scheen AJ, Paquot N, Lefèbvre PJ.
    Expert Opin Investig Drugs; 2017 Dec; 26(12):1373-1389. PubMed ID: 29052441
    [Abstract] [Full Text] [Related]

  • 4. Glucagon receptor antagonists for the treatment of type II diabetes: current prospects.
    Djuric SW, Grihalde N, Lin CW.
    Curr Opin Investig Drugs; 2002 Nov; 3(11):1617-23. PubMed ID: 12476962
    [Abstract] [Full Text] [Related]

  • 5. Computational identification of novel natural inhibitors of glucagon receptor for checking type II diabetes mellitus.
    Grover S, Dhanjal JK, Goyal S, Grover A, Sundar D.
    BMC Bioinformatics; 2014 Nov; 15 Suppl 16(Suppl 16):S13. PubMed ID: 25521597
    [Abstract] [Full Text] [Related]

  • 6. Glucagon receptor signaling in metabolic diseases.
    Wewer Albrechtsen NJ.
    Peptides; 2018 Feb; 100():42-47. PubMed ID: 29412830
    [Abstract] [Full Text] [Related]

  • 7. Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes.
    Ali S, Drucker DJ.
    Am J Physiol Endocrinol Metab; 2009 Mar; 296(3):E415-21. PubMed ID: 19116373
    [Abstract] [Full Text] [Related]

  • 8. Fibroblast growth factor 21 mediates specific glucagon actions.
    Habegger KM, Stemmer K, Cheng C, Müller TD, Heppner KM, Ottaway N, Holland J, Hembree JL, Smiley D, Gelfanov V, Krishna R, Arafat AM, Konkar A, Belli S, Kapps M, Woods SC, Hofmann SM, D'Alessio D, Pfluger PT, Perez-Tilve D, Seeley RJ, Konishi M, Itoh N, Kharitonenkov A, Spranger J, DiMarchi RD, Tschöp MH.
    Diabetes; 2013 May; 62(5):1453-63. PubMed ID: 23305646
    [Abstract] [Full Text] [Related]

  • 9. Alpha-cells and therapy of diabetes: Inhibition, antagonism or death?
    Klempel N, Thomas K, Conlon JM, Flatt PR, Irwin N.
    Peptides; 2022 Nov; 157():170877. PubMed ID: 36108978
    [Abstract] [Full Text] [Related]

  • 10. First proof of pharmacology in humans of a novel glucagon receptor antisense drug.
    van Dongen MG, Geerts BF, Morgan ES, Brandt TA, de Kam ML, Romijn JA, Cohen AF, Bhanot S, Burggraaf J.
    J Clin Pharmacol; 2015 Mar; 55(3):298-306. PubMed ID: 25197025
    [Abstract] [Full Text] [Related]

  • 11. Fibroblast growth factor 21 (FGF21) and glucagon-like peptide 1 contribute to diabetes resistance in glucagon receptor-deficient mice.
    Omar BA, Andersen B, Hald J, Raun K, Nishimura E, Ahrén B.
    Diabetes; 2014 Jan; 63(1):101-10. PubMed ID: 24062250
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Polyomic profiling reveals significant hepatic metabolic alterations in glucagon-receptor (GCGR) knockout mice: implications on anti-glucagon therapies for diabetes.
    Yang J, MacDougall ML, McDowell MT, Xi L, Wei R, Zavadoski WJ, Molloy MP, Baker JD, Kuhn M, Cabrera O, Treadway JL.
    BMC Genomics; 2011 Jun 01; 12():281. PubMed ID: 21631939
    [Abstract] [Full Text] [Related]

  • 15. Glucagon and regulation of glucose metabolism.
    Jiang G, Zhang BB.
    Am J Physiol Endocrinol Metab; 2003 Apr 01; 284(4):E671-8. PubMed ID: 12626323
    [Abstract] [Full Text] [Related]

  • 16. Small molecule glucagon receptor antagonists: a patent review (2011 - 2014).
    Filipski KJ.
    Expert Opin Ther Pat; 2015 Jul 01; 25(7):819-30. PubMed ID: 25828189
    [Abstract] [Full Text] [Related]

  • 17. Advances in non-peptide glucagon receptor antagonists.
    Madsen P, Brand CL, Holst JJ, Knudsen B.
    Curr Pharm Des; 1999 Sep 01; 5(9):683-691. PubMed ID: 10495358
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. desHis¹Glu⁹-glucagon-[mPEG] and desHis¹Glu⁹(Lys³⁰PAL)-glucagon: long-acting peptide-based PEGylated and acylated glucagon receptor antagonists with potential antidiabetic activity.
    Irwin N, Franklin ZJ, O'Harte FP.
    Eur J Pharmacol; 2013 Jun 05; 709(1-3):43-51. PubMed ID: 23562625
    [Abstract] [Full Text] [Related]

  • 20. Absence of glucagon and insulin action reveals a role for the GLP-1 receptor in endogenous glucose production.
    Jun LS, Millican RL, Hawkins ED, Konkol DL, Showalter AD, Christe ME, Michael MD, Sloop KW.
    Diabetes; 2015 Mar 05; 64(3):819-27. PubMed ID: 25288673
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.